Short Term Price Target on Astrazeneca PLC (AZN)

Astrazeneca PLC (NYSE:AZN) : 3 Wall Street analysts covering Astrazeneca PLC (NYSE:AZN) believe that the average level the stock could reach for the short term is $35.55. The maximum price target given is $37 and the minimum target for short term is around $34, hence the standard deviation is calculated at $1.38.

Shares of AstraZeneca PLC rose by 3.07% in the last five trading days and 2.51% for the last 4 weeks. AstraZeneca PLC is up 6.98% in the last 3-month period. Year-to-Date the stock performance stands at -8.2%. Also, In the latest statement by the brokerage house, Leerink Swann maintains its outlook on Astrazeneca PLC (NYSE:AZN). The current rating of the shares is Market Perform, according to the research report released by the firm. The brokerage firm lowers the price target from $38 per share to $34 per share. The rating by the firm was issued on May 2, 2016.

Astrazeneca PLC (NYSE:AZN) : 5 analysts are covering Astrazeneca PLC (NYSE:AZN) and their average rating on the stock is 2.6, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Astrazeneca PLC (NYSE:AZN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $29.63 and $29.59 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.19, notching a gain of 1.14% for the day. The total traded volume was 5,627,490 . The stock had closed at $29.85 on the previous day.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.